Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition. Eligibility isn't automatic at those numbers, though — a prescriber assesses the full clinical picture before any treatment begins. If you're trying to work out whether you qualify, this page walks through the factors that matter, so you can go into a consultation knowing where you stand.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The licensed BMI thresholds give the starting point, not the answer. A BMI reading of 30 places you within the licensed range, but a prescriber still reviews your medical history, current medicines, and any conditions that might make semaglutide unsuitable before deciding. That isn't bureaucracy for its own sake, it reflects how the medicine works and the real variation between patients.
The BMI requirements for Wegovy are straightforward enough on paper. In practice, someone with a BMI of 28 and well-controlled type 2 diabetes sits in a different clinical position from someone with the same BMI and no comorbidities. The prescriber's job is to distinguish between them. If you want a quick sense of whether you might be eligible for Wegovy, the NHS BMI calculator is a useful first step before booking anything.
It's also worth knowing that some conditions rule Wegovy out regardless of BMI. A personal or close family history of medullary thyroid carcinoma, a diagnosis of multiple endocrine neoplasia type 2, or previous pancreatitis are examples your prescriber will ask about. Pregnancy, breastfeeding, and trying to conceive are also situations in which Wegovy is not recommended. Under-18s are not licensed to use it.
Most people reading this are trying to decide between waiting for NHS access and exploring a private route. That's a genuinely difficult call, and the criteria are not the same in both cases.
NICE's recommendation for Wegovy (semaglutide) on the NHS sets a higher bar: a BMI of 35 or above, at least one weight-related comorbidity, and access only within a specialist weight management service with multidisciplinary support. Treatment is time-limited to two years under NHS guidance. NICE's full appraisal (TA875) sets out the detail, including the lower thresholds for certain ethnic backgrounds. Waiting lists for specialist services are commonly long.
A private prescription follows the licensed criteria rather than the NHS commissioning threshold, so a BMI of 30 (or 27 with a qualifying condition) is the operative standard. That's a meaningful difference for people who meet the licence but fall short of the NHS criteria. For a closer look at how the two pathways compare in practice, the Wegovy eligibility overview goes into that in more detail. And if cost is part of the decision, the Wegovy pricing page is the clearest place to see what a private prescription involves.
If your BMI is between 27 and 29.9, a weight-related condition isn't just helpful) it's required. The conditions the licence recognises include type 2 diabetes, hypertension, dyslipidaemia (high cholesterol or triglycerides), obstructive sleep apnoea, and cardiovascular disease. Prediabetes and osteoarthritis also commonly feature in a prescriber's assessment.
Having one of those conditions doesn't make approval automatic, but it does change the clinical calculus. A prescriber reviewing your case will look at how well controlled those conditions are, which medicines you already take, and whether there are any interactions to weigh up. Who can take Wegovy covers some of those interaction questions if you want to read further before a consultation.
On the other side, certain medicines and diagnoses shift the picture. Oral contraceptives may be less reliably absorbed while on semaglutide, so a prescriber may discuss contraceptive choices with you, this is something NHS England's guidance on weight management injections addresses directly. It's one of several practical considerations that gets missed when people focus only on the BMI number.
A consultation with a prescriber isn't a tick-box exercise. At nume, your answers are read the same day by a GPhC-registered prescriber (a real clinician, not an automated system) and identity and weight are verified before any treatment is approved. That process protects you as much as it protects the prescriber's clinical judgement.
The most useful preparation is honest: have your weight and height to hand, think through your current medications and any relevant diagnoses, and be ready to discuss your history with conditions like gallbladder disease or pancreatitis. If you've been on a weight-loss injection before and want to transfer your care, your prescriber will ask for evidence of your current dose. The steps for becoming eligible for Wegovy page gives a clear picture of what the process looks like end to end.
If you're broadly eligible and want to find out for certain, start your free consultation, our prescribers review every case individually and can tell you clearly whether Wegovy is appropriate for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.